Dr. Andika aktif di berbagai organisasi profesi tingkat nasional dan internasional. Dia tergabung di Ikatan Ahli Urologi Indonesia (IAUI). Untuk organisasi internasional, Dr. Andika begabung di International Continance Society (ICS) dan Endoruology Society.
Beberpa penelitiannya sudah di publikasikan di jurnal urologi berskala internasional, seperti International Journal of Urology dan Asian Journal of Surgery. Penelitian dr. Andika mencakup kanker prostat di Indonesia, khususnya kanker prostat yang sudah mengalami penyebaran ke tulang. Selain itu, penelitiannya mengenai bedah minimal invasif untuk donor ginjal hidup juga berhasil masuk ke jurnal berskala internasional.
Pelayanan kesehatan, khususnya di bidang Urologi mencakup batu saluran kencing, pembesaran prostat, infeksi saluran kencing dapat dilayani olehnya. Selain itu, dr. Andika juga memberikan pelayanan di bidang men’s health (Disfungsi Ereksi, Ejakulasi Prematur dan Gangguan Libido pada pria)
Objectives : To analyze predictive clinical factors of survival in bone‐metastatic prostate cancer, and to develop a prognostic nomogram for patients with this condition.
Methods : The present study included 392 patients with bone‐metastatic prostate cancer treated with androgen deprivation therapy. Pretreatment parameters were analyzed using the Cox proportional hazards model to identify the predictors of overall survival.
Laparoscopic donor nephrectomy has become the standard procedure to procure kidney graft. Transplantation using multiple arteries allograft is technically more challenging and still controversial with respect to renal transplantation outcomes. The objective of this study was to examine the transplantation outcome in both donor and recipient outcome of multiple arteries allograft kidney compared with single renal artery kidney.
Aim: Metastatic prostate cancer (mPCa) has a poor outcome with median survival of two to five years. The use of androgen deprivation therapy (ADT) is a gold standard in management of this stage. Aim of this study is to analyze the prognostic value of PSA kinetics of patient treated with hormonal therapy related to survival from several published studies
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were developed, including multi-targeted tyrosine kinase inhibitors (TKI), the mammalian target of rapamycin (mTOR) complex-1 kinase inhibitors, and the humanized antivascular endothelial growth factor (VEGF) monoclonal antibody. Hence, the objective of this article was to critically examine the current evidence of targeted therapy treatment for patients with mRCC